** U.S.-listed shares of German drugmaker CureVac 5CV.DE, CVAC.O rise 15.4% to $3.23 premarket
** European Patent Office upheld a CVAC mRNA patent after it was challenged by rival BioNTech 22UAy.DE, co said on Thursday
** A German court will decide on July 1 if BioNTech infringed this patent
** The dispute is part of a larger ongoing patent battle between CureVac and BioNTech over mRNA tech used in COVID-19 vaccines
** CVAC fell 8.2% in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.